Skip to main content

buprenorphine / naloxone (Suboxone®)

 

Following a full submission

AWMSG advice

Status: Recommended with restrictions

Buprenorphine/naloxone (Suboxone®) is recommended for restricted use within NHS Wales as substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. In accordance with NICE guidance such treatment should be considered in patients who are unsuitable for maintenance treatment with methadone.

 Final Recommendation: buprenorphine/naloxone (Suboxone) 70 (PDF, 151Kb)

Medicine details

Medicine name buprenorphine / naloxone (Suboxone®)
Formulation 8 mg / 2 mg sublingual tablet and 2 mg / 0.5 mg sublingual tablet
Reference number 70
Indication

Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction

Company Merck Sharp & Dohme Ltd
BNF chapter Central nervous system
Submission type Full
Status Recommended with restrictions
Advice number 1108
NMG meeting date 14/05/2008
AWMSG meeting date 13/06/2008
Ratification by Welsh Government 17/07/2008
Date of issue 18/07/2008
Follow AWTTC: